1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required By NIH

 
• By Sarah Karlin-Smith

Pulling the controversial Alzheimer’s drug’s BLA should not exempt Biogen from fulfilling ClinicalTrials.gov reporting requirements for two key studies, even if the research gets terminated, former head of the NIH data repository tells the Pink Sheet.

puzzle in shape of human head with missing pieces in brain
Clinicaltrials.gov reporting requirements should help fill in some data gaps on Aduhelm despite end of commercialization. • Source: Shutterstock

Biogen, Inc.’s decision to discontinue commercialization and terminate its ongoing research with Alzheimer’s treatment Aduhelm does not appear to release the sponsor from data transparency requirements associated with the laws and regulations governing the US’s ClinicalTrials.gov data bank.

Key Takeaways

  • US government appears to have levers to ensure that Aduhelm’s post-market trials report results publicly – something critics of the now defunct drug believe is important given the controversy surrounding its accelerated approval and the data’s relevance to other drugs being marketed and studied in Alzheimer’s.

Critics of the US Food and Drug Administration’s decision to grant Aduhelm (aducanumab-avwa) accelerated approval are now further frustrated by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.